Authors: Francis Davies, Future Science Group
The UK government has allocated £30 million worth of funding for antimicrobial resistance (AMR) across four novel projects as part of the Global AMR Innovation Fund (GAMRIF). The projects will predominantly benefit low- to middle-income countries where the prevalence and cost of infection is greatest. GAMRIF are also involved with a UK–China AMR collaboration and InnoVet-AMR, with the Canadian International Development Research Centre.
The greatest portion of the funding, £20 million, will be allocated to the non-profit international partnership, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. Their research is focused on the most dangerous drug-resistant bacteria and the funding will support global research on the development of novel vaccines and alternatives-to-antibiotics against drug-resistant bacterial infection.